It is also interesting to speculate that the observed increase in S1P is related to the reported JAK2 activated changes in PP2a [54] which has been shown to selectively eradicate drug-resistant CML stem cells [55]. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.